Novartis received approval from the U.S. Food and Drug Administration for the Swiss pharmaceuticals company’s drug Beovu to treat a cause of vision loss.

Harnessing the increasingly important applications of artificial intelligence, researchers from Genentech and parent company Roche have developed what is being called the first “deep learning model” that can predict which patients with diabetic retinopathy will progress the fastest.

Novartis has teamed up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily impact of wet age-related macular degeneration and empower those living with wet AMD and their caregivers to make simple, functional changes to support safety and independence at home.

The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.

Novartis announced that the U.S. Food and Drug Administration accepted the company’s Biologics License Application for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration.

Days after rejecting Regeneron’s attempt to secure a supplemental approval for Eylea, the FDA approved a new dosing label for the drug in wet age-related macular degeneration (wet AMD).

The U.S. FDA rejected Regeneron Pharmaceuticals’ attempt to secure a supplemental approval for the Tarrytown, N.Y.-based company’s blockbuster drug Eylea as a once-per 12-week treatment for wet age-related macular degeneration.

Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.

Novartis’ bid to move in on Bayer’s and Regeneron’s eye-drug turf was buoyed by data showing patients on the Swiss drugmaker’s new RTH258 drug showed less disease activity than those on its rivals’ drug Eylea.

Regeneron Pharmaceuticals reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for its flagship eye treatment Eylea and new eczema drug Dupixent.